Showing 2630 results
- https://www.novartis.com/news/media-releases/novartis-brolucizumab-rth258-demonstrates-superiority-versus-aflibercept-key-secondary-endpoint-measures-disease-activity-namd-leading-cause-blindnessBrolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
- https://www.novartis.com/news/media-releases/novartis-reports-positive-results-from-phase-iii-trial-kisqali-ribociclib-combination-therapy-premenopausal-women-hrher2-advanced-or-metastatic-breast-cancerMONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal…
- https://www.novartis.com/news/media-releases/novartis-announces-study-data-demonstrating-cosentyx-reduced-signs-and-symptoms-psoriatic-arthritis-while-inhibiting-progression-joint-structural-damageStructural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced…
- https://www.novartis.com/news/media-releases/novartis-seeks-leadership-cosentyx-showing-no-radiographic-progression-ankylosing-spondylitis-4-yearsFor the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx® have no radiographic progression of the spine at 4 years[1] These new data…
- https://www.novartis.com/news/media-releases/novartis-reaches-another-regulatory-milestone-ctl019-tisagenlecleucel-submission-its-maa-ema-children-young-adults-rr-b-cell-all-and-adult-patients-rr-dlbclApplication follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis…
- https://www.novartis.com/news/media-releases/sandoz-invites-young-entrepreneurs-enter-sandoz-hack-global-competition-help-solve-healthcare-access-challengesDespite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need Sandoz "HACk" - Healthcare Access Challenge - is…
- https://www.novartis.com/news/media-releases/novartis-receives-three-new-fda-approvals-expanded-use-ilaris-treating-rare-periodic-fever-syndrome-conditionsIlaris® (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA…
- https://www.novartis.com/news/media-releases/novartis-announces-positive-top-line-results-from-ascend-4-phase-iii-trial-zykadia-untreated-adult-alk-nsclc-patientsIn a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
- https://www.novartis.com/news/media-releases/novel-novartis-malaria-compound-shows-potential-be-effective-against-infections-resistant-all-currently-available-antimalarial-drugsResults published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites…
- https://www.novartis.com/news/media-releases/important-new-analysis-shows-novartis-entresto-associated-higher-relative-health-related-quality-life-scores-among-hfref-patientsNew analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 263
- › Next page